EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)

Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk

Brian A Bergmark iD, Nicholas A Marston, Thomas A Prohaska, Veronica J Alexander, André Zimerman, Filipe A Moura, Sabina A Murphy, Erica L Goodrich, Shuanglu Zhang, Daniel Gaudet, Ewa Karwatowska-Prokopczuk, Sotirios Tsimikas und 3 weitere

New England Journal of Medicine · 16.05.2024 · 390 (19) · 1770-1780

DOI: 10.1056/nejmoa2402309 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 16.05.2024. Verfasst von Brian A Bergmark und 14 weiteren Autor:innen. Beteiligte Einrichtung: From the TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston (B.A.B., N.A.M., A.Z…. Hauptthemen laut MEDLINE: Hypertriglyceridemia, Apolipoprotein C-III, Triglycerides, Cardiovascular Diseases. Die Arbeit wurde bisher 215-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Ionis Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertriglyceridemiaApolipoprotein C-IIITriglyceridesCardiovascular DiseasesOligonucleotidesHumansMiddle AgedMaleFemaleAgedAdultDouble-Blind MethodOligonucleotides, AntisenseHeart Disease Risk FactorsCholesterol, LDLHypolipidemic AgentsApolipoproteins B

Substanzen

Apolipoprotein C-IIITriglyceridesOligonucleotidesOligonucleotides, AntisenseCholesterol, LDLHypolipidemic AgentsApolipoproteins B

Autor:innen und Institutionen

  • From the TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston (B.A.B., N.A.M., A.Z., F.A.M., S.A.M., E.L.G., S.Z., R.P.G., M.S.S.); Ionis Pharmaceutical…

ORCID-Profile: Brian A Bergmark

Förderung

  • Ionis Pharmaceuticals

Zitieren

APA

Bergmark, B. A., Marston, N. A., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Murphy, S. A., Goodrich, E. L., Zhang, S., Gaudet, D., Karwatowska-Prokopczuk, E., Tsimikas, S., Giugliano, R. P., Sabatine, M. S., & Bridge–TIMI 73a Investigators (2024). Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. New England Journal of Medicine, 390(19), 1770-1780. https://doi.org/10.1056/nejmoa2402309

Vancouver

Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, et al. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. New England Journal of Medicine. 2024;390(19):1770-1780. doi:10.1056/nejmoa2402309

BibTeX
@article{Bergmark2024,
  author = {Bergmark, Brian A and Marston, Nicholas A and Prohaska, Thomas A and Alexander, Veronica J and Zimerman, André and Moura, Filipe A and Murphy, Sabina A and Goodrich, Erica L and Zhang, Shuanglu and Gaudet, Daniel and Karwatowska-Prokopczuk, Ewa and Tsimikas, Sotirios and Giugliano, Robert P and Sabatine, Marc S and Bridge–TIMI 73a Investigators, Bridge–TIMI 73a Investigators},
  title = {Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {390},
  number = {19},
  pages = {1770--1780},
  doi = {10.1056/nejmoa2402309}
}
Kostenlos starten →